Patent Branch Vessel | Occluded/Stenotic Branch Vessel | Univariate P Value | Multivariate P Value | OR (95% CI) | |
---|---|---|---|---|---|
Mean patient age (yr) | 54.6 ± 12.6 | 56.0 ± 10.9 | .426 | ||
Male | 19/148 (12.8%) | 11/69 (15.9%) | .537 | ||
Mean max aneurysm sac size | 6.0 ± 4.0 | 5.6 ± 3.7 | .096 | .415 | 0.94 (0.82–1.09) |
Mean aneurysm neck size | 3.6 ± 1.7 | 3.4 ± 1.2 | .054 | .534 | 0.91 (0.67–1.22) |
Acutely ruptured target lesion | 4/148 (2.7%) | 4/69 (5.8%) | .260 | ||
Mean procedural time (min) | 205 ± 65 | 210 ± 66 | .658 | ||
Mean fluoroscopy time (min) | 65 ± 37 | 60 ± 30 | .365 | ||
>1 PED deployed | 14/148 (9.5%) | 4/69 (5.8%) | .362 | ||
% PED classic | 60/148 (40.5%) | 32/69 (46.3%) | .418 | ||
Balloon angioplasty | 12/148 (8.1%) | 2/69 (2.9%) | .146 | ||
Mean PED diameter (mm) | 4.0 ± 0.5 | 3.8 ± 0.5 | .013 | .029 | 0.46 (0.23–0.92) |
Mean Δmax size of parent vessel and PED | 0.21 ± 0.17 | 0.27 ± 0.25 | .057 | .142 | 3.60 (0.65–19.89) |
Mean Δmin size of parent vessel and PED | 0.78 ± 0.4 | 0.70 ± 0.42 | .226 | ||
Branch vessel incorporation into aneurysm sac | 42/148 (28.3%) | 16/69 (27.5%) | .898 | ||
Mean periprocedural P2Y12 | 127 ± 68 | 125 ± 74 | .855 | ||
Intraprocedural administration of abciximab | 9/148 (6.1%) | 11/69 (15.9%) | .019 | .030 | 4.26 (1.15–15.78) |
Presence of endothelial hyperplasia | 31/146 (21.2%) | 22/68 (32.4%) | .079 | .504 | 1.31 (0.59–2.94) |
Mean length of DSA follow-up (mo) | 18.8 ± 19.4 | 18.0 ± 8.2 | .584 | ||
A1 ACA | 3/11 (27.2%) | 8/11 (72.7%) | 0.003 | .114 | 3.12 (0.76–12.81) |
Anterior choroidal artery | 30/31 (96.8%) | 1/31 (3.2%) | <.001 | .003 | 0.04 (0.004–0.32) |
PcomA | 22/39 (56.4%) | 17/39 (43.6%) | .081 | .248 | 1.57 (0.73–3.40) |
Ophthalmic artery | 90/125 (71.2%) | 36/125 (28.8%) | .23 |
Note:—PcomA indicates posterior communicating artery; AcomA, anterior communicationg.
↵a Percentages reflect analysis per branch vessel.